Aytu Biopharma (AYTU) EBT Margin (2013 - 2026)
Aytu Biopharma (AYTU) reported EBT Margin of 45.19% for Q1 2026, down 6588.0% year-over-year from 0.7% in Q1 2025, and up 35.26% quarter-over-quarter from 69.79% in Q4 2025.
Aytu Biopharma (AYTU) EBT Margin (2013 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 14 years of EBT Margin data on file, last reported at 45.19% in Q1 2026.
- EBT Margin for Q1 2026 came in at 45.19%, down 6588.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 59.49% (down 6429.0% YoY), and the FY2025 annual result was 20.71%, down 478.0% from the prior year.
- EBT Margin climbed to 45.19% in Q1 2026 per AYTU's latest filing, from 69.79% in the prior quarter.
- Over five years, EBT Margin peaked at 20.69% in Q1 2025 and troughed at 220.22% in Q1 2022.
- A 5-year average of 35.78% and a median of 17.39% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2025: EBT Margin surged 18855 bps in 2023, then tumbled 11108 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 25.47% in 2022, then soared by 129 bps to 7.46% in 2023, then sank by 68 bps to 2.35% in 2024, then plunged by 3064 bps to 69.79% in 2025, then jumped by 35 bps to 45.19% in 2026.
- Business Quant data shows AYTU's EBT Margin at 45.19% in Q1 2026, 69.79% in Q4 2025, and 14.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | -45.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.19% |
| Dec 31, 2025 | -69.79% |
| Sep 30, 2025 | 14.15% |
| Jun 30, 2025 | -128.46% |
| Mar 31, 2025 | 20.69% |
| Dec 31, 2024 | 2.35% |
| Sep 30, 2024 | 9.04% |
| Jun 30, 2024 | -17.39% |
| Mar 31, 2024 | -12.60% |
| Dec 31, 2023 | 7.46% |
| Sep 30, 2023 | -41.94% |
| Jun 30, 2023 | -7.99% |
| Mar 31, 2023 | -31.67% |
| Dec 31, 2022 | -25.47% |
| Sep 30, 2022 | -2.53% |
| Jun 30, 2022 | -58.62% |
| Mar 31, 2022 | -220.22% |
| Dec 31, 2021 | -49.95% |
| Sep 30, 2021 | -127.68% |
| Jun 30, 2021 | -79.80% |